Enzychem Lifesciences Corporation (KOSDAQ:183490)

Market Cap	88.50B -24.4%
Revenue (ttm)	72.17B -12.1%
Net Income	-24.31B
EPS	-310.21
Shares Out	77.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	239,224
Average Volume	412,917
Open	1,128.00
Previous Close	1,140.00
Day's Range	1,108.00 - 1,141.00
52-Week Range	937.00 - 1,766.00
Beta	1.01
RSI	32.93
Earnings Date	Mar 20, 2026

About Enzychem Lifesciences

Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea. It is also developing EC-18, an oral small molecule for fibrotic diseases, such as nonalcoholic steatohepatitis; and in severe respiratory diseases as a potential therapy for COVID-19. The company was founded in 1999 and is headquartered in Seoul, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 130
• Stock Exchange: KOSDAQ
• Ticker Symbol: 183490

Financial Performance

In 2024, Enzychem Lifesciences's revenue was 77.38 billion, an increase of 1.76% compared to the previous year's 76.04 billion. Losses were -22.11 billion, 137.0% more than in 2023.